letetresgene autoleucel (GSK3377794) / Adaptimmune 
Welcome,         Profile    Billing    Logout  
 13 Diseases   3 Trials   3 Trials   119 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
letetresgene autoleucel (GSK3377794) / Adaptimmune
NCT06703346: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants with NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Active, not recruiting
2
87
Europe, Canada, US
Experimental: Letetresgene autoleucel
Adaptimmune
Neoplasms
09/24
07/26
NCT05993299: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Active, not recruiting
2
7
Europe, Canada, US
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Adaptimmune
Neoplasms
10/22
07/25
IGNYTE-ESO, NCT03967223 / 2019-000415-87: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Active, not recruiting
2
103
Europe, Canada, US
Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
Adaptimmune
Neoplasms
09/24
07/26
2018-003949-42: A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients.

Not yet recruiting
1/2
54
Europe
GSK3377794, Pembrolizumab, GSK3377794, MK-3475, Dispersion for infusion, Solution for infusion, KEYTRUDA
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A.
Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC), Non-Small Cell Lung Cancer (NSCLC), Diseases [C] - Cancer [C04]
 
 

Download Options